Wat wij financieren (alleen in het Engels)

Funded projects
1,200+
Men's Health Partners
20
Countries
21
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Adam Garone, Executive Director, Chief Mo Bro​
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” Therese Fitzpatrick, Global Mental Health Lead.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

Priority driven Collaborative Cancer Research Scheme 2007-2012

Country
Australia
Co-funded
Cancer Australia
Implemented by
Prostate Cancer Foundation of Australia
Report Card Date
31 July 2014
Reporting period
July 2007 to July 2014
Project Status
Project Completed

AUD 3,709,211

Movember Funding to Date

What we seek to achieve

To reduce the impact of cancer in the community and improve outcomes for people affected by cancer.To work collaboratively with organisations that support cancer research to generate evidence, increase knowledge, and improve the translation of research into policy and practice.

How the project works

The PdCCRS aims to fund research in tumour areas that place a high burden of disease on the Australian community; fund applied cancer research projects that directly relate to the identified priorities of Cancer Australia and PCFA and fund research that can directly improve cancer outcomes by influencing clinical practice, policy and/or care.

Research funded through this scheme is Outcome-/Impact-focused. Applicants must be able to demonstrate how their project has the potential to improve short, medium and long term outcomes in cancer care and/or cancer control. Applicants must demonstrate how their research will benefit populations with poorer outcomes within the community, such as Aboriginal and Torres Strait Islander peoples and those living in particular socioeconomic status areas and geographic locations.

Every project presents a clear pathway to translation; Applicants are required to describe the approaches and methodologies that will be employed to translate findings of the proposed research into clinical practice, policy, and/ or further research in order to improve cancer care and/ or cancer control. Applicants must also discuss how the proposed collaboration is necessary for the translation of results. All PdCCRS funded projects are collaborative. These project grants demonstrate necessary collaborations that may be cross-disciplinary, national, multi-state or international, and the applicants describe the specific role of the key collaborators in the project. Importantly, PdCCRS grants engage consumers. Consumer involvement in the project must be substantive, meaningful and bi-directional.

PCFA signs an annual co-funding agreement with Cancer Australia for a set amount of contribution which is matched dollar per dollar by Cancer Australia or/and other partners that participate in the scheme and fund prostate cancer research.

What we are doing / have done

Fourteen new, multi-state and multidisciplinary teams were funded through this period accounting for more than 70 experts nationally and internationally. PdCCRS grants co-funded by Movember and Cancer Australia have generated 24 peer reviewed publications. Knowledge/data generated through research into these funded projects has been presented in 74 national and 27 International conferences.

From 2007-2012, a total of 14 grants of a total value $7,767,518 have been funded - Movember contribution through PCFA’s Research Programs equates to $3,709,211 which indicates a leverage of 209%. During 2007-2011, an additional 12 grants at a total of $5.1M relating to PCFA’s research priorities was funded through the PdCCRS by other organisations (including Cancer Australia). In addition, an estimated $2.3M funding was secured through listing in the competitive grants register. This funding is dedicated to infrastructure. Completed research funded under the PdCCRS has had direct impact in the lives of men living with prostate cancer via:
2007-2012 two new patents were issued:
i. M. Lackmann (CA 491195) Provisional Patent Application: Detection of EphA3 as a Marker of the Presence of Solid Tumors. Lackmann, M., Scott, A.M., To, C., Bebbinton, C.R. , Yarranton, G.T., Baer, M., Palath, V., Assignee: KaloBios Pharmaceuticals, Inc., 260 E. Grand Ave, South San Francisco, CA 94080, filed: 18th June 2010, Townsend & Townsend Attorney Docket No.: 021167-004000US
ii. M. Lackmann (CA 491195) A PCT claiming the use of IIIA4 as anti-vascular agent targeting EphA3+ and EphA3- tumours has been filed (WO2008112192-A2; WO2008112192-A3; US2008286272-A1, KaloBios Pharmaceuticals, Inc.)
- direct recruitment in trials funded by the scheme - Horvath et al and Davis et al- clinical development of new therapies - The IIIA4 anti-EphA3 monoclonal antibody as an investigational anti-cancer therapeutic (Lackmann et al.) has now entered clinical trial for blood cancers. Investigators are seeking venture capital to start human trials in prostate cancer.
- providing real world data on treatment outcomes under non-trial conditions
- A pilot Prostate Cancer Register provided a snapshot of prostate cancer treatment care in Victoria that was otherwise unavailable (Millar et al). Findings from this study have been communicated to the Department of Health to influence policy, practice and research
- enabling maturation of pre-clinical studies into Phase II and III studies. Pre-clinical results obtained by Butler et al, have made the basis of a proposed pharmacodynamics clinical trial to assess the biological effects of AUY922 when administered to patients with localised prostate cancer prior to surgery.
- securing continuation of funding from other agencies to translate the results
- completed grants have reported leveraging more than 5,000,000 dollars through other sources that is directly linked to studies co-funded by Movember and Cancer Australia.
- generating new knowledge that informs new directions in research into prostate cancer

For a detailed list of funded Australian Prostate Cancer research projects, please CLICK HERE.

Close this report card

For more information on this project or any of the Movember Funded Projects please contact programs@movember.com

>
Page 1 of 19